1. Efavirenz Pharmacokinetics and Human Immunodeficiency Virus Type 1 (HIV-1) Viral Suppression Among Patients Receiving Tuberculosis Treatment Containing Daily High-Dose Rifapentine . (16th December 2021) Authors: Podany, Anthony T; Pham, Michelle; Sizemore, Erin; Martinson, Neil; Samaneka, Wadzanai; Mohapi, Lerato; Badal-Faesen, Sharlaa; Dawson, Rod; Johnson, John L; Mayanja, Harriet; Lalloo, Umesh; Whitworth, William C; Pettit, April; Campbell, Kayla; Phillips, Patrick P J; Bryant, Kia; Scott, Nigel; Ver... Journal: Clinical infectious diseases Issue: Volume 75:Number 4(2022) Page Start: 560 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Rifapentine With and Without Moxifloxacin for Pulmonary Tuberculosis in People With Human Immunodeficiency Virus (S31/A5349). (30th August 2022) Authors: Pettit, April C; Phillips, Patrick P J; Kurbatova, Ekaterina; Vernon, Andrew; Nahid, Payam; Dawson, Rodney; Dooley, Kelly E; Sanne, Ian; Waja, Ziyaad; Mohapi, Lerato; Podany, Anthony T; Samaneka, Wadzanai; Savic, Rada M; Johnson, John L; Muzanyi, Grace; Lalloo, Umesh G; Bryant, Kia; Sizemore, Eri... Journal: Clinical infectious diseases Issue: Volume 76:Number 3(2023) Page Start: e580 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗